The Bio Report

Orbis Medicines is developing orally available synthetic macrocycles called ⁿCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.

Pharma Boardroom

As pharmaceutical companies race to replace injectable therapies with more accessible oral biologics, Orbis Medicines is leading the charge with its next-generation macrocycle platform and AI-powered discovery engine.

Base to Base Biotech by Jim Cornall

Orbis Medicines is revolutionizing macrocycle drug development by combining AI, big data, and high-throughput synthesis to make this complex class of molecules reliably designable and orally available for the first time.

Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark’s first AI supercomputer, Gefion, which is owned and operated by DCAI.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific Officer, President, Pfizer Research & Development, as Chairperson of the Board of Directors.

Endpoints News

European biotech Orbis Medicines has raised €90 million in Series A funding to advance its AI-driven platform for designing oral macrocycle drugs targeting diseases traditionally treated with injectable biologics.

Biopharma Dive

Orbis Medicines has raised $93 million to develop oral macrocyclic peptides that combine the power of biologics with the convenience of pills, aiming to replace injectable drugs for hard-to-treat disease targets.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a significant expansion of its operations and capabilities by establishing itself at Symbion’s new biotech hub in Fuglebakken, Copenhagen.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral biologic therapies for major diseases.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.